Rubella Virus, Live Attenuated

Summary

Rubella Virus, Live Attenuated (CHEMBL6068355) is an approved vaccine component; indicated across 2 conditions including rubella.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Vaccine component
• Indications: 2 conditions

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6068355
Name	Rubella Virus, Live Attenuated
Type	Vaccine component
Max phase	4

Also known as: Rubella virus, live attenuated, live attenuated component of m-m-rvaxpro, live attenuated component of proquad, RUBELLA VIRUS, LIVE ATTENUATED

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
rubella	4	MONDO:0004656	EFO:1002026

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).